The proposition is: abiraterone acetate and prednisolone are recommended to be available as a routine commissioning treatment option within the criteria set out in this policy for newly diagnosed high-risk hormone-sensitive metastatic prostate cancer.

This is an interim clinical commissioning policy pending the outcome of a National Institute for Health and Care Excellence evaluation of the use of generic abiraterone acetate in this high-risk hormone-sensitive metastatic prostate cancer population.